TORONTO, ONTARIO--(Marketwired - Aug. 17, 2016) - Pivotal Therapeutics Inc. is in default of CSE requirements. Effective at market close, Pivotal Therapeutics, currently the subject of a Cease Trade Order, will be suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules.